List of essential medicines approved in Ghana
Categories
Tags
You May Also Like
Introduction
For exporters targeting Ghana, the Ghana Essential Medicines List (EML), managed by the Ghana National Drugs Programme under the Ministry of Health, is a key reference point alongside FDA Ghana product registration. Where FDA registration determines whether a specific product can legally enter the market, the EML shapes what public hospitals, health centers, and Ghana’s National Health Insurance Scheme (NHIS) actually procure and reimburse.
This guide covers how Ghana’s EML is structured and what it means for exporters planning market entry.
What Is the Ghana Essential Medicines List?
<cite index=”24-1″>Essential medicines are those that satisfy the priority healthcare needs of the population, selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness.</cite> <cite index=”24-1″>Ghana’s EML is derived from its companion Standard Treatment Guidelines, ensuring harmony between clinical treatment, procurement, and reimbursement decisions.</cite>
<cite index=”25-1″>The list uses the Recommended International Non-proprietary Name (rINN) for all medicines, in line with WHO recommendations and practice</cite> — a detail worth noting for exporters preparing product documentation and labeling for the Ghanaian market.
Important distinction for exporters: the EML is separate from FDA Ghana product registration. FDA registration and the accompanying import permit are what legally allow a specific product into Ghana. The EML instead reflects what the public health system is structured to procure, prescribe, and — critically in Ghana’s case — reimburse through NHIS.
How Ghana's EML Is Structured
Ghana’s EML has two structural features that distinguish it from Nigeria’s and Kenya’s essential medicines lists, both worth understanding before entering the market.
Facility-Level Coding
<cite index=”32-1″>Medicines are grouped by the facility level at which they can be prescribed and dispensed: Level A (Community), Level M (Midwifery), Level B1 (Health Centre without Doctor), Level B2 (Health Centre with Doctor), Level C (District Hospital), Level D (Regional/Teaching Hospital), Level SD (Specialist Drugs), and Level PD (Programme Drugs).</cite> <cite index=”25-1″>Specialist Drugs are restricted to use by qualified specialists, while Programme Drugs are used specifically within Ministry of Health public health programmes and their guidelines.</cite>
This matters directly for exporters: a product’s facility-level classification affects which type of buyer — community clinic, district hospital, or teaching hospital — will realistically be procuring it.
NHIS Reimbursement Status
<cite index=”25-1″>Medicines are also marked as either reimbursed (R) or not reimbursed (NR) by the National Health Insurance Authority, based on the NHIS benefits package.</cite> A product’s reimbursement status has a direct effect on procurement volume, since NHIS-reimbursed medicines see substantially higher institutional demand than non-reimbursed equivalents.
Key Therapeutic Categories on the EML
While the exact category count varies by edition, the EML follows the WHO Model List structure, with categories most relevant to exporters including:
1. Anti-Infective Medicines
Antibiotics, antimalarials, and antiviral agents — consistently the highest-volume category given Ghana’s infectious disease burden.
2. Anti-HIV / Antiretroviral Medicines
Tied to Ghana’s national HIV treatment program and typically NHIS-reimbursed given their public health priority status.
3. Maternal and Child Health Medicines
Includes midwifery-level (Level M) medicines specifically, reflecting Ghana’s facility-level structure for maternal care access.
4. Medicines for Non-Communicable Diseases
A growing category as Ghana’s disease burden shifts toward chronic conditions alongside infectious disease.
5. Specialist and Programme Drugs
Restricted-use categories (Level SD and PD) covering complex conditions and Ministry of Health public health programmes specifically — relevant for exporters supplying more specialized or programmatic products.
Why the EML Matters for Exporters
âś” NHIS reimbursement status affects real demand A product’s R/NR marking has a direct bearing on how much institutional buyers will actually order — worth checking before prioritizing a product for Ghana.
âś” Facility-level coding shapes buyer targeting Understanding whether a product is classified for community, district, or specialist-level use helps target the right distributor and institutional relationships.
âś” rINN naming affects documentation Product naming across FDA registration documents and marketing materials should align with rINN conventions used in the EML.
✔ Distinct from, but complementary to, FDA registration An EML-aligned, NHIS-reimbursed product still requires full FDA Ghana registration and import permit — both processes matter independently.
How Exporters Can Use This Information
âś” Check NHIS reimbursement status for target products before prioritizing them for the Ghanaian market
âś” Align product naming and documentation with rINN conventions used in Ghana’s EML and Standard Treatment Guidelines
âś” Match your product’s facility-level classification to the right type of distributor or institutional buyer relationship
âś” Prioritize FDA Ghana registration for products in high-reimbursement, high-priority EML categories
Conclusion
Ghana’s EML stands out for its facility-level coding and NHIS reimbursement structure — details that directly shape which buyers will procure a given product and at what volume. Exporters who understand this structure, on top of securing FDA Ghana registration and import permits, are better positioned to match their product portfolio to how Ghana’s healthcare system actually buys.
Partnering with an experienced pharma export company in India familiar with both FDA Ghana requirements and EML/NHIS structures helps align product strategy with actual market demand rather than guesswork.